The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease
emphasises the need for consensus recommendations on the rational use of biomarkers to …

Importance Amyloid positron emission tomography (PET) allows the direct assessment of
amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this …

Purpose Epidemiological and logistical reasons are slowing the clinical validation of the
molecular imaging biomarkers in the initial stages of neurocognitive disorders. We provide …

INTRODUCTION Recent work suggests that amyloid beta (Aβ) positron emission
tomography (PET) tracer uptake shortly after injection (“early phase”) reflects brain …

Introduction Amyloid-β (Aβ) plaques is a significant hallmark of Alzheimer's disease (AD),
detectable via amyloid-PET imaging. The Fluorine-18-Fluorodeoxyglucose ([18F] FDG) PET …

Objective To study the correlation between a static PET image of the first-minute-frame
(FMF) acquired with 18 F-labeled amyloid-binding radiotracers and brain [18 F] FDG PET in …

Amyloid plaques are a neuropathologic hallmark of Alzheimer's disease (AD), which can be
imaged through positron emission tomography (PET) technology using …

A 74-year-old man was referred to the neurologist for memory complaint. As prodromal AD
was suspected, the patient underwent cerebrospinal fluid (CSF) biomarker evaluation which …

PET imaging is increasingly recognized as an important diagnostic tool to investigate
patients with 25 cognitive disturbances of possible neurodegenerative origin. PET with 2 …

Purpose Visual interpretation of brain amyloid-β (Aβ) PET can be difficult in individuals with
borderline Aβ burden. Coregistration with individual MRI is recommended in these cases …